November 21, 2026
$RichWire Markets and money, explained simply
LIVE
Walmart Shares Waver Despite Topping Estimates as Growth Momentum Cools Bitcoin Slips Below Key Support Level as Bearish Technical Structure Takes Hold Bitcoin Tests Support Following Drop Below $60,000 Milestone Evaluating HF Sinclair and the Turning Oil Refining Cycle Bitcoin Technical Outlook Signals Persistent Bearish Structure Despite Short-Term Bounce Mapping Out a $500 Stake in Two Emerging Quantum Computing Enterprises Bitcoin Eyes Resistance Near $61,800 Following Support Bounce Analyst Suggests Taking Profits on Global X MSCI Colombia ETF Anthropic IPO Momentum Fades as Stock Slips Below Opening Levels Bitcoin Tests Critical Monthly Support Level as Traders Watch for Breakdown or Rebound Bitcoin Tests $58,000 Put Wall Following Market Flush CG Oncology Fair Value Revised Following Phase 3 Clinical Results Walmart Shares Waver Despite Topping Estimates as Growth Momentum Cools Bitcoin Slips Below Key Support Level as Bearish Technical Structure Takes Hold Bitcoin Tests Support Following Drop Below $60,000 Milestone Evaluating HF Sinclair and the Turning Oil Refining Cycle Bitcoin Technical Outlook Signals Persistent Bearish Structure Despite Short-Term Bounce Mapping Out a $500 Stake in Two Emerging Quantum Computing Enterprises Bitcoin Eyes Resistance Near $61,800 Following Support Bounce Analyst Suggests Taking Profits on Global X MSCI Colombia ETF Anthropic IPO Momentum Fades as Stock Slips Below Opening Levels Bitcoin Tests Critical Monthly Support Level as Traders Watch for Breakdown or Rebound Bitcoin Tests $58,000 Put Wall Following Market Flush CG Oncology Fair Value Revised Following Phase 3 Clinical Results

EyePoint Pharmaceuticals Shares Phase III Trial Results for Retinal Drug DURAVYU

🏢 Companies 1 min read 👁 4

EyePoint Pharmaceuticals executives discussed recent Phase III clinical trial outcomes for its flagship retinal disease treatment, DURAVYU, at the UBS Global Biopharma Conference.

EyePoint Pharmaceuticals Shares Phase III Trial Results for Retinal Drug DURAVYU🏢Companies

Photo: Seeking Alpha

Key points

  • EyePoint presented at the UBS Global Biopharma Conference on November 17, 2026.
  • Phase III LUGANO and LUCIA trials for wet AMD missed their primary non-inferiority endpoints against Eylea.
  • Two fully enrolled clinical trials for diabetic macular edema remain underway.

EyePoint Pharmaceuticals executives outlined the current status of their drug pipeline at the UBS Global Biopharma Conference, highlighting recent clinical data for their leading product candidate, DURAVYU. Jay Duker, President and CEO, along with George Elston, Executive VP and CFO, addressed investors regarding the company's tyrosine kinase inhibitor developed for major retinal indications.

Duravyu, a vorolanib intravitreal insert, is designed to target vascular endothelial growth factor receptors, platelet-derived growth factor, and JAK1. The company recently reported top-line Phase III results from two wet age-related macular degeneration trials, named LUGANO and LUCIA. According to company leadership, neither trial achieved its primary endpoint, which measured non-inferiority in visual acuity change compared to the on-label two-milligram dose of Eylea, although management noted favorable secondary endpoints.

Following the wet AMD results, EyePoint continues to advance its fully enrolled clinical trials for diabetic macular edema. Management emphasized ongoing evaluation of their data and pipeline strategy as they navigate these developmental milestones.

What to watch next: Further updates on the ongoing diabetic macular edema trials and management's strategic next steps following the wet AMD trial outcomes.

Source Seeking Alpha — seekingalpha.com/article/4968997-eyepoint-inc-eypt-presents-at-ubs-glob… ↗

Contact the newsroom

Got a tip, a proposal or a partnership question? Write to us and we will reply shortly.